Опухолевые маркеры при скрининге и мониторинге больных раком мочевого пузыря

1. Давыдов М.И., Аксель Е.М. Злокачественные образования в России и странах СНГ в 2001 г. — М., 2003.

2. Клиническая онкоурология / Под ред. Б.П.Матвеева.— М., 2003. — С.197—225.

3. Sensitivity and specificity: paper by A.Saad et al. // B. J. U. International. — 2002. — Vol. 89(4). March. — Р. 369—373.

4. Poulakis V., Witzsch U., De Vries R. et al. А comparison of urinary nuclear matrix protein — 22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results // ВJU International. — 2001. —88. — 692—701.

5. Сергеева Н.С., Маршутина Н.В. Новые серологические и уринологические опухолевые маркеры в уточняющей диагностике и мониторинге онкологических больных: Материалы VII Российского онкологического конгресса.

6. Lee E. Ponsky, Shashikala Narma, Lakshimi Pandrangi et al. Screening and monitoring for bladder cancer: refining the use of NMP 22 // J. Urol. — July, 2001. — Vol.166; 75—78.

7. Del Nero Al., Esposito N., Curro A. et al. Evaluation of Urinary Level of NMP 22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test // Eur. Urology. — 1999; 35; 93—97.

8. Steiner G., Schoenberg M.P., Linn J.F. Detection of bladder cancer recurrence by microsatellite analysis of urine // Nat. Med. — 1997; 3: 621.

9. Sharma S., Zippe C., Pandrangi L. et al. Exclusion Criteria Enhance the Specificity and Positive Predictive Value of NMP 22 and BTA STAT // J. Urol. — July, 1999:162; 53—57.

10. Akaza H., Miyanaga N. et al. Evaluation of Urinary NMP 22 (Nuclear Matrix Protein 22) as a Diagnostic Marker for Urothelial Cancer — Screening for Urothelial Cancer in Patients with Microscopic Hematuria // Jpn. J. Cancer Chemotherapy. — 1997; 24 (7): 837—842.

11. Stampfer D.A., Campinito G.A., Rodriguez-Villanueva J. et al. Evaluation of NMP 22 in the Detection of Transitional Cell Carcinoma of the Bladder // J. Urol. — February, 1998; 158: 1899—1901.

12. landman J., Kavaler E., Chang Y. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer. — New York, NY (Presented by Dr. Landman) // J. Urol. — June, 1998; 159: 47—52.

13. Landman J., Droller M.J. and B. C-S. Liu et al. Evaluation of Urinary Nuclear Matrix Protein (NMP 22) as a Potential Screening Marker for Transitional Cell Carcinoma of the Urinary Tract. — Mt. Sinai Medical Center, New York, NY. The Sixth European Urological Winter Forum, Davos, Switzerland. — February 16—21, 1997.

14. Landman J., Chang Y., Kavalier E. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer // Urology. — Sentember, 1998; 52(3): 398—402.